Article

Simultaneous vertical guided bone regeneration and guided tissue regeneration in the posterior maxilla using recombinant human platelet-derived growth factor: a case report.

Loma Linda University, Loma Linda, Calif, USA.
Journal of Oral Implantology (Impact Factor: 1.15). 01/2009; 35(5):251-6. DOI: 10.1563/AAID-JOI-D-09-00004.1
Source: PubMed

ABSTRACT This clinical case report describes and demonstrates successful use of recombinant human platelet-derived growth factor (rhPDGF-BB) in conjunction with autogenous bone, anorganic bone mineral, and barrier membranes to reconstruct severe alveolar bone defects. A combined sinus augmentation and vertical alveolar ridge augmentation was successfully performed. In addition, a significant amount of periodontal bone gain was achieved in close apposition to a previously denuded root surface, which is significant from a periodontal standpoint, given the possibility of vertical periodontal regeneration.

1 Bookmark
 · 
53 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Leukocyte- and platelet-rich fibrin (L-PRF) is a biomaterial commonly used in periodontology and implant dentistry to improve healing and tissue regeneration, particularly as filling material in alveolar sockets to regenerate bone for optimal dental implant placement. The objective of this work was to evaluate the use of L-PRF as a safe filling and hemostatic material after dental extractions (or avulsions) for the prevention of hemorrhagic complications in heart surgery patients without modification of the anticoagulant oral therapy. Fifty heart surgery patients under oral anticoagulant therapy who needed dental extractions were selected for the study. Patients were treated with L-PRF clots placed into 168 postextraction sockets without modification of anticoagulant therapy (mean international normalized ratio  =  3.16 ± 0.39). Only 2 patients reported hemorrhagic complications (4%), all of which resolved a few hours after the surgery by compression and hemostatic topical agents. Ten patients (20%) showed mild bleeding, which spontaneously resolved or was resolved by minimal compression less than 2 hours after surgery. No case of delayed bleeding was reported. The remaining 38 patients (76%) showed an adequate hemostasis after the dental extractions. In all cases, no alveolitis or painful events were reported, soft tissue healing was quick, and wound closure was always complete at the time of suture removal one week after surgery. The proposed protocol is a reliable therapeutic option to avoid significant bleeding after dental extractions without the suspension of the continuous oral anticoagulant therapy in heart surgery patients. Other applications of the hemostatic and healing properties of L-PRF should be investigated in oral implantology.
    Journal of Oral Implantology 06/2011; 37(6):681-90. · 1.15 Impact Factor
  • Source
    09/2011; , ISBN: 978-953-307-481-8
  • [Show abstract] [Hide abstract]
    ABSTRACT: Provide a comprehensive overview on the clinical use and the efficacy of growth factors in different reconstructive procedures in the oral maxillofacial area. A systematic review of the literature on the clinical use of human and human recombinant growth factors in oral maxillofacial reconstruction has been performed. The use of autogenous growth factors in platelet concentrates (PCs) has shown to be beneficial in the treatment of intrabony pockets at a reasonable level of evidence by improving probing depth and clinical attachment levels as well as linear bone fill within the limits of the observation periods. The application in conjunction with non-autogenous graft materials has been superior to the use of PCs only or grafting materials alone. No benefits have been shown for the use of PCs in recession treatment. When used in furcation treatment, probing depth, clinical attachment level and linear bone fill have been reported to improve significantly, however, without clinical benefit. No benefit for the final outcome could be shown for the use of PCs neither in sinus lift procedures nor in lateral / vertical crest augmentations. The use of human recombinant growth factors has been so far limited almost exclusively to rhPDGF-BB and rhBMPs (BMP-2, BMP-7 and GDF-5). The use of rhPDGF in the treatment of intrabony pockets has shown a reliable increase in linear bone fill but weaker evidence for permanent improvements of clinical attachment level. So far there is no evidence to support the use in recession treatment, sinus lift procedures and socket healing as well as lateral / vertical augmentations of the alveolar crest. rhBMPs have shown to be effective in enhancing bone formation in socket healing (rhBMP-2) and sinus lift procedures (rhBMP-2 and GDF-5). No controlled studies are available for the use in mandibular segmental repair. Successful reports on this application appear to be limited to primary reconstruction after ablative surgery for benign pathology with preservation of the periosteum. Evidence of clinical efficacy of growth factors in reconstructive procedures in the oral and maxillofacial area is limited.
    Clinical Implant Dentistry and Related Research 07/2013; · 3.82 Impact Factor

Full-text

View
6 Downloads
Available from
Aug 15, 2014